The subsidiary named LSK NRDO (no research development only) is a bio-venture business model that focuses on development, clinical trials and commercialization by acquiring candidates for new drug candidates with high potential for success.
LSK NRDO signed an agreement this month with Dongkuk University's industry-academy collaboration team on the transfer of patent and technology for solid tumor treatment called "DGG-200338." Solid tumors are an abnormal mass of tissue that usually does not contain cysts or liquid areas.
LSK NRDO plans to complete first-phase clinical trials for solid tumors by 2021. The company aims to build a new pharmaceutical industry ecosystem that will support the development of new drugs.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.